HHS Cancels 22 mRNA Vaccine Contracts, Citing Ineffectiveness Against Respiratory Viruses
In a sweeping move that marks a major shift in U.S. vaccine policy, the Department of Health and Human Services (HHS) announced Tuesday it has canceled 22 contracts worth nearly $500 million related to mRNA vaccine development. The decision follows a weeks-long internal review by HHS’s Biomedical Advanced Research and Development Authority (BARDA).